哮喘和慢性阻塞性肺疾病药物处方索赔：COVID-19疫情下英格兰国家处方的时间序列分析（2019年1月至2020年10月）

数据集获取（Figshare）

• 源站标题：Asthma and COPD medicines prescription-claims: A time-series analysis of England’s national prescriptions during the COVID-19 pandemic (Jan 2019 to Oct 2020)
• DOI：10.6084/m9.figshare.17130023.v1
• 发布日期：2021-12-06
• 文件数：4 个
• 文件总体积：1.23 MB
• 源站页面：https://tandf.figshare.com/articles/dataset/Asthma_and_COPD_medicines_prescription-claims_A_time-series_analysis_of_England_s_national_prescriptions_during_the_COVID-19_pandemic_Jan_2019_to_Oct_2020_/17130023

命令行下载

curl -L -o "IERX supp.pdf" "https://ndownloader.figshare.com/files/31672724"
curl -L -o "IERX supp1.pdf" "https://ndownloader.figshare.com/files/31672727"
curl -L -o "IERX supp2.pdf" "https://ndownloader.figshare.com/files/31672730"
curl -L -o "IERX supp3.pdf" "https://ndownloader.figshare.com/files/31672733"

文件清单

• IERX supp.pdf（577.86 KB）
• IERX supp1.pdf（394.69 KB）
• IERX supp2.pdf（206.09 KB）
• IERX supp3.pdf（50.07 KB）

文件总体积 1.23 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

During the pandemic, there have been disruptions to how patients seek care.
To investigate monthly prescription claims for asthma and chronic obstructive pulmonary disease (COPD) medicines during the first UK wave, interrupted time series (ITS) analysis was used. A national cohort of community patients’ data were examined.
Descriptive statistics show salbutamol, aminophylline, ipratropium, and theophylline remain below pre-pandemic levels.
Montelukast showed pre-pandemic monthly increase (Est. 67,151 doses, P = 0.05, 95% CI: 1011, 133,291), followed by a jump of 1.6 million doses at March , followed by monthly declines (Est. −112,098 doses, P = 0.216, 95% CI: -293,499, 69,303).
Before the pandemic, tiotropium, salbutamol, aminophylline, and ipratropium (P = 0.003) show monthly declines but theophylline and beclometasone showed increases. In March , salbutamol (P = 0.033) and ipratropium (P = 0.001) show a significant jump. After March , ipratropium continues with a downward trajectory (P = 0.001), with a generalized negative trend for all other agents. Salbutamol confidence bounds become negative after March 2020. Some brands were unavailable.
An ‘unmet’ medical gap is identified. While it is essential to understand the underlying reasons, urgent action needs to be taken to reassess patients and ensure continuity of care.
PLAIN LANGUAGE SUMMARIES (PLS)
Asthma and chronic obstructive pulmonary disease (COPD) are long-term lung conditions, affecting 6 million & 1.2 million people respectively and causing breathing difficulties. Sufferers are at a higher risk of chest infections including the coronavirus. Regular use of prescribed medication stabilizes these conditions and prevents them from getting worse. It is common to be prescribed a combination of five to eight oral and inhaled medications.
We investigated the impact of the pandemic on the dispensing of these specific medicines across England during the first wave. The English Prescribing Dataset was checked from January 2019 to February 2020 (14 months before the pandemic) and March to October 2020 (8 months after its onset).
We find that since March 2020, salbutamol, aminophylline, ipratropium, and

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.17130023.v1（source: https://tandf.figshare.com/articles/dataset/Asthma_and_COPD_medicines_prescription-claims_A_time-series_analysis_of_England_s_national_prescriptions_during_the_COVID-19_pandemic_Jan_2019_to_Oct_2020_/17130023）。